<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00463437</url>
  </required_header>
  <id_info>
    <org_study_id>109507</org_study_id>
    <nct_id>NCT00463437</nct_id>
  </id_info>
  <brief_title>Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines</brief_title>
  <official_title>Booster Vaccination With Pneumococcal Vaccine GSK1024850A, a DTPa-Combined and MenC or Hib-MenC Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety in terms of fever (rectal temperature)
      higher than 39 degree Celcius (°C) and the immunogenicity in terms of antibody response
      following a booster vaccination with pneumococcal vaccine GSK1024850A at 11 to 18 months of
      age in children previously primed with the same vaccines including a pneumococcal conjugate
      vaccine co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined and
      meningococcal serogroup C (MenC) or combined meningococcal serogroup C and Haemophilus
      influenzae type b (Hib-MenC) vaccine.

      This protocol posting deals with objectives &amp; outcome measures of the booster phase. The
      objectives &amp; outcome measures of the primary phase are presented in a separate protocol
      posting (NCT number = NCT00334334).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)</measure>
    <time_frame>During the 4-day (Day 0-3) period after the booster vaccination</time_frame>
    <description>Fever was measured as rectal temperature.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms</measure>
    <time_frame>During the 4-day (Day 0-3) period after the booster vaccination</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms</measure>
    <time_frame>During the 4-day (Day 0-3) period after the booster vaccination</time_frame>
    <description>Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AE)</measure>
    <time_frame>During the 31-day (Day 0-30) period after the booster vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAE)</measure>
    <time_frame>During the 31-day (Day 0-30) period after the booster vaccination</time_frame>
    <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAE)</measure>
    <time_frame>From the beginning of the study up to the end of the extended 6-month safety follow-up period</time_frame>
    <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value</measure>
    <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
    <description>Anti-pneumococcal antibody concentration cut-off value assessed was 0.05 microgram per milliliter (µg/mL).
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off Value</measure>
    <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
    <description>Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was ≥ 8.
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value</measure>
    <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
    <description>Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL).
The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off Value</measure>
    <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
    <description>Anti-pneumococcal antibody cut-off value assessed was ≥ 8.
The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off Value</measure>
    <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
    <description>Anti-protein D antibody cut-off value assessed was ≥ 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off Value</measure>
    <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
    <description>Meningococcal serogroup C serum bactericidal assay titer cut-off value assessed was ≥ 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off Value</measure>
    <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
    <description>Anti-meningococcal polysaccharide C antibody cut-off value assessed was ≥ 0.3 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off Value</measure>
    <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
    <description>Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was ≥ 0.15 µg/mL.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1437</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Acellular Pertussis</condition>
  <condition>Tetanus</condition>
  <condition>Poliomyelitis</condition>
  <condition>Diphtheria</condition>
  <arm_group>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevenar™ + Menitorix™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal conjugate vaccine GSK1024850A</intervention_name>
    <description>Intramuscular injection, 1 dose.</description>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</arm_group_label>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</arm_group_label>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar</intervention_name>
    <description>Intramuscular injection, 1 dose.</description>
    <arm_group_label>Prevenar™ + Menitorix™</arm_group_label>
    <other_name>Pneumococcal conjugate vaccine (Wyeth Lederle).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix hexa</intervention_name>
    <description>Intramuscular injection, 1 dose. In Germany and Poland.</description>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</arm_group_label>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</arm_group_label>
    <other_name>DTPa-HBV-IPV/Hib (GSK Biologicals).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix IPV Hib</intervention_name>
    <description>Intramuscular injection, 1 dose. In Spain.</description>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</arm_group_label>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</arm_group_label>
    <other_name>DTPa-IPV/Hib (GSK Biologicals).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix penta</intervention_name>
    <description>Intramuscular injection, 1 dose. In Germany and Poland.</description>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</arm_group_label>
    <arm_group_label>Prevenar™ + Menitorix™</arm_group_label>
    <other_name>DTPa-HBV-IPV (GSK Biologicals).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix IPV</intervention_name>
    <description>Intramuscular injection, 1 dose. In Spain.</description>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</arm_group_label>
    <arm_group_label>Prevenar™ + Menitorix™</arm_group_label>
    <other_name>DTPa-IPV (GSK Biologicals)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningitec</intervention_name>
    <description>Intramuscular injection, 1 dose.</description>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</arm_group_label>
    <other_name>Meningococcal C conjugate vaccine (Wyeth).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeisVac-C</intervention_name>
    <description>Intramuscular injection, 1 dose.</description>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</arm_group_label>
    <other_name>Meningococcal C conjugate vaccine (Baxter).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Menitorix</intervention_name>
    <description>Intramuscular injection, 1 dose.</description>
    <arm_group_label>GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</arm_group_label>
    <arm_group_label>Prevenar™ + Menitorix™</arm_group_label>
    <other_name>Combined Hib-MenC vaccine (GSK Biologicals).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol.

          -  A male or female between, and including, 11-18 months of age at the time of the
             booster vaccination.

          -  A male or female who previously participated in study 107005 and received three doses
             of pneumococcal conjugate vaccine.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

        Exclusion Criteria:

          -  Concurrently participating in another clinical study, at any time during the study
             period (active phase and extended safety follow-up), in which the subject has been or
             will be exposed to an investigational or a non-investigational product.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within one month preceding the booster dose of study vaccines, or
             planned use during the entire study period

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within 6 months prior to the booster dose of study vaccines.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol,
             during the period starting one month before the booster dose of study vaccines and up
             to the follow-up visit (one month after the booster dose of study vaccines).

          -  Administration of any pneumococcal, diphtheria, tetanus, pertussis, polio, hepatitis
             B, Haemophilus influenzae type b, MenC and/or Hib-MenC vaccines other than the study
             vaccines from study 107005.

          -  History of, or intercurrent, diphtheria, tetanus, pertussis, polio, hepatitis B,
             Haemophilus influenzae type b, meningococcal serogroup C disease.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  History of seizures (this criterion does not apply to subjects who have had a single,
             uncomplicated febrile convulsion in the past) or progressive neurological disease.

          -  Acute disease at the time of enrolment.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  A family history of congenital or hereditary immunodeficiency.

          -  Major congenital defects or serious chronic illness.

          -  Administration of immunoglobulins and/or any blood products within three months
             preceding the booster dose of study vaccines or planned administration during the
             active phase of the study (starting with the administration of the booster dose of
             study vaccines up to the follow-up visit one month after).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Saulgau</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boennigheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bretten</city>
        <state>Baden-Wuerttemberg</state>
        <zip>75015</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ettenheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77955</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Wuerttemberg</state>
        <zip>76189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kehl</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oberstenfeld</city>
        <state>Baden-Wuerttemberg</state>
        <zip>71720</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schwaebisch-Hall</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tettnang</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cham</city>
        <state>Bayern</state>
        <zip>93413</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81735</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Noerdlingen</city>
        <state>Bayern</state>
        <zip>86720</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olching</city>
        <state>Bayern</state>
        <zip>82140</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roding</city>
        <state>Bayern</state>
        <zip>93426</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eschwege</city>
        <state>Hessen</state>
        <zip>37269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Niedernhausen</city>
        <state>Hessen</state>
        <zip>65527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolfenbuettel</city>
        <state>Niedersachsen</state>
        <zip>38302</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hille</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Loehne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32584</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porta Westfalica</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Kreuznach</city>
        <state>Rheinland-Pfalz</state>
        <zip>55543</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bodenheim</city>
        <state>Rheinland-Pfalz</state>
        <zip>55294</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankenthal</city>
        <state>Rheinland-Pfalz</state>
        <zip>67227</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gerolstein</city>
        <state>Rheinland-Pfalz</state>
        <zip>54568</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54294</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worms</city>
        <state>Rheinland-Pfalz</state>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Doebeln</city>
        <state>Sachsen</state>
        <zip>04720</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singwitz</city>
        <state>Sachsen</state>
        <zip>02692</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lobenstein</city>
        <state>Thueringen</state>
        <zip>07356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weimar</city>
        <state>Thueringen</state>
        <zip>99425</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12679</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wola</city>
        <zip>43-225</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Blanes (Girona)</city>
        <zip>17300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burgos</city>
        <zip>09005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28047</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montgat/Barcelona</city>
        <zip>08390</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Málaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Móstoles/Madrid</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sant Vicenç dels Horts /Barcelona</city>
        <zip>08620</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tona/Barcelona</city>
        <zip>08551</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valladolid</city>
        <zip>47010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vélez-Málaga / Málaga</city>
        <zip>29700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S109-18. doi: 10.1097/INF.0b013e318199f62d. Review.</citation>
    <PMID>19325447</PMID>
  </reference>
  <reference>
    <citation>Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S97-S108. doi: 10.1097/INF.0b013e318199f61b. Review.</citation>
    <PMID>19325452</PMID>
  </reference>
  <reference>
    <citation>Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S77-88. doi: 10.1097/INF.0b013e318199f609.</citation>
    <PMID>19325450</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2007</study_first_submitted>
  <study_first_submitted_qc>April 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2007</study_first_posted>
  <results_first_submitted>June 11, 2009</results_first_submitted>
  <results_first_submitted_qc>June 11, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2009</results_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fever.</keyword>
  <keyword>Meningococcal disease.</keyword>
  <keyword>Pneumococcal disease.</keyword>
  <keyword>Meningococcal vaccine.</keyword>
  <keyword>Pneumococcal vaccine.</keyword>
  <keyword>Immunogenicity.</keyword>
  <keyword>Booster vaccination.</keyword>
  <keyword>Safety.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>109507</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109507</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109507</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109507</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109507</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109507</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109507</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
          <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
        </group>
        <group group_id="P2">
          <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
          <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
        </group>
        <group group_id="P3">
          <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
          <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
        </group>
        <group group_id="P4">
          <title>Prevenar™ + Menitorix™</title>
          <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="359"/>
                <participants group_id="P2" count="363"/>
                <participants group_id="P3" count="358"/>
                <participants group_id="P4" count="357"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="355"/>
                <participants group_id="P2" count="352"/>
                <participants group_id="P3" count="352"/>
                <participants group_id="P4" count="350"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
          <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
        </group>
        <group group_id="B2">
          <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
          <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
        </group>
        <group group_id="B3">
          <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
          <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Prevenar™ + Menitorix™</title>
          <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="359"/>
            <count group_id="B2" value="363"/>
            <count group_id="B3" value="358"/>
            <count group_id="B4" value="357"/>
            <count group_id="B5" value="1437"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.3" spread="1.81"/>
                    <measurement group_id="B2" value="14.3" spread="1.74"/>
                    <measurement group_id="B3" value="14.3" spread="1.78"/>
                    <measurement group_id="B4" value="14.3" spread="1.78"/>
                    <measurement group_id="B5" value="14.3" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="171"/>
                    <measurement group_id="B5" value="724"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="163"/>
                    <measurement group_id="B4" value="186"/>
                    <measurement group_id="B5" value="713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)</title>
        <description>Fever was measured as rectal temperature.</description>
        <time_frame>During the 4-day (Day 0-3) period after the booster vaccination</time_frame>
        <population>Analysis was performed on the Total vaccinated cohort from Pn-HibC and Pr-HibC Groups on subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)</title>
          <description>Fever was measured as rectal temperature.</description>
          <population>Analysis was performed on the Total vaccinated cohort from Pn-HibC and Pr-HibC Groups on subjects for whom data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="355"/>
                <count group_id="O4" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
        <time_frame>During the 4-day (Day 0-3) period after the booster vaccination</time_frame>
        <population>Subjects from the Total Vaccinated cohort for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
          <population>Subjects from the Total Vaccinated cohort for whom data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="357"/>
                <count group_id="O3" value="355"/>
                <count group_id="O4" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="195"/>
                    <measurement group_id="O3" value="193"/>
                    <measurement group_id="O4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O2" value="183"/>
                    <measurement group_id="O3" value="186"/>
                    <measurement group_id="O4" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="150"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.</description>
        <time_frame>During the 4-day (Day 0-3) period after the booster vaccination</time_frame>
        <population>Subjects from the Total Vaccinated cohort for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.</description>
          <population>Subjects from the Total Vaccinated cohort for whom data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="357"/>
                <count group_id="O3" value="355"/>
                <count group_id="O4" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="139"/>
                    <measurement group_id="O4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38.0 °C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="190"/>
                    <measurement group_id="O3" value="191"/>
                    <measurement group_id="O4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>During the 31-day (Day 0-30) period after the booster vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="358"/>
                <count group_id="O4" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
        <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>During the 31-day (Day 0-30) period after the booster vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
          <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="358"/>
                <count group_id="O4" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
        <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>From the beginning of the study up to the end of the extended 6-month safety follow-up period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
          <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="358"/>
                <count group_id="O4" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value</title>
        <description>Anti-pneumococcal antibody concentration cut-off value assessed was 0.05 microgram per milliliter (µg/mL).
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
        <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value</title>
          <description>Anti-pneumococcal antibody concentration cut-off value assessed was 0.05 microgram per milliliter (µg/mL).
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1 pre (n=150,152,149, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="140"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-1 post (n=158,152,160,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 pre (n=153,156,150,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="156"/>
                    <measurement group_id="O3" value="147"/>
                    <measurement group_id="O4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 post (n=158,153,160,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5 pre (n=149,146,146,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="144"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5 post (n=157,153,160,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B pre (n=151,155,150,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="144"/>
                    <measurement group_id="O4" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B post (n=158,153,160,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="158"/>
                    <measurement group_id="O4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F pre (n=149,153,148,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="147"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F post (n=158,152,160,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V pre (n=149,155,149,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="154"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V post (n=158,153,160,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 pre (n=153,158,152,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="152"/>
                    <measurement group_id="O4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 post (n=158,153,160,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C pre (n=151,153,145,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="145"/>
                    <measurement group_id="O4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C post (n=157,152,160,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F pre (n=143,146,139,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="139"/>
                    <measurement group_id="O4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F post (n=158,151,160,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F pre (n=152,156,150,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="144"/>
                    <measurement group_id="O4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F post (n=158,153,160,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="158"/>
                    <measurement group_id="O4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off Value</title>
        <description>Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was ≥ 8.
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F.</description>
        <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off Value</title>
          <description>Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was ≥ 8.
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opsono-1 pre (n=144,145,141,143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-1 post (n=140,139,140,137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="127"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-4 pre (n=104,121,112,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-4 post (n=137,134,140,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="140"/>
                    <measurement group_id="O4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-5 pre (n=116,114,117,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-5 post (n=124,130,136,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="131"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-6B pre (n=133,132,133,137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-6B post (n=142,135,142,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="135"/>
                    <measurement group_id="O4" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-7F pre (n=111,122,115,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-7F post (n=140,137,139,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="137"/>
                    <measurement group_id="O3" value="139"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-9V pre (n=133,133,130,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="122"/>
                    <measurement group_id="O4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-9V post (n=143,139,143,137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="139"/>
                    <measurement group_id="O3" value="143"/>
                    <measurement group_id="O4" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-14 pre (n=121,125,114,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="107"/>
                    <measurement group_id="O4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-14 post (n=137,138,138,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="138"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-18C pre (n=126,118,123,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-18C post (n=121,129,121,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="121"/>
                    <measurement group_id="O4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19F pre (n=127,135,134,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19F post (n=137,137,139,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="139"/>
                    <measurement group_id="O4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-23F pre (n=132,136,128,137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-23F post (n=145,143,146,143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="143"/>
                    <measurement group_id="O3" value="146"/>
                    <measurement group_id="O4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value</title>
        <description>Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL).
The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
        <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value</title>
          <description>Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL).
The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-6A pre (n=145,144,144,149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="119"/>
                    <measurement group_id="O4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A post (n=156,152,159,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="145"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A pre (n=145,153,145,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="121"/>
                    <measurement group_id="O4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A post (n=157,153,160,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="155"/>
                    <measurement group_id="O4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off Value</title>
        <description>Anti-pneumococcal antibody cut-off value assessed was ≥ 8.
The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
        <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off Value</title>
          <description>Anti-pneumococcal antibody cut-off value assessed was ≥ 8.
The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opsono-6A pre (n=108,110,106,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-6A post (n=127,128,128,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="117"/>
                    <measurement group_id="O4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19A pre (n=133,138,136,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19A post (n=124,132,130,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off Value</title>
        <description>Anti-protein D antibody cut-off value assessed was ≥ 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
        <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off Value</title>
          <description>Anti-protein D antibody cut-off value assessed was ≥ 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre (n=147,153,147,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="138"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post (n=158,152,160,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off Value</title>
        <description>Meningococcal serogroup C serum bactericidal assay titer cut-off value assessed was ≥ 8.</description>
        <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off Value</title>
          <description>Meningococcal serogroup C serum bactericidal assay titer cut-off value assessed was ≥ 8.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre (n=68,65,66,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post (n=89,84,79,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off Value</title>
        <description>Anti-meningococcal polysaccharide C antibody cut-off value assessed was ≥ 0.3 µg/mL.</description>
        <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off Value</title>
          <description>Anti-meningococcal polysaccharide C antibody cut-off value assessed was ≥ 0.3 µg/mL.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre (n=126,124,125,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post (n=156,149,159,149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="159"/>
                    <measurement group_id="O4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off Value</title>
        <description>Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was ≥ 0.15 µg/mL.</description>
        <time_frame>Before (pre) and one month after (post) the booster administration</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
            <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar™ + Menitorix™</title>
            <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off Value</title>
          <description>Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was ≥ 0.15 µg/mL.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre (n=147,144,150,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="145"/>
                    <measurement group_id="O4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post (n=157,153,160,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™</title>
          <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Wyeth’s Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.</description>
        </group>
        <group group_id="E2">
          <title>GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™</title>
          <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals’ DTPa-combined vaccine (Infanrix™ hexa in Germany &amp; Poland and Infanrix™ IPV Hib in Spain) and Baxter’s Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.</description>
        </group>
        <group group_id="E3">
          <title>GSK’s 10-valent Pneumococcal Vaccine 1024850A + Menitorix™</title>
          <description>Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
        </group>
        <group group_id="E4">
          <title>Prevenar™ + Menitorix™</title>
          <description>Subjects receiving a booster dose of Wyeth’s pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany &amp; Poland and Infanrix™ IPV in Spain) and GSK Biologicals’ combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15"/>
                <counts group_id="E2" subjects_affected="9"/>
                <counts group_id="E3" subjects_affected="13"/>
                <counts group_id="E4" subjects_affected="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchpneumopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="196"/>
                <counts group_id="E2" subjects_affected="195"/>
                <counts group_id="E3" subjects_affected="193"/>
                <counts group_id="E4" subjects_affected="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="195" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="193" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="165" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="186" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="173" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="150" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="134" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="139" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="108" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="191" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="157" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="363"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

